Dermal application of lactic acid based cream of a non pathogenic Kocuria marina (BMKO1) strain against Epidermophyton floccosum (MTCC 613) symptomatic excision mice model by Dash, Soumya S & Pattnaik, Smaranika
Dash et al                                                                                                                Journal of Drug Delivery & Therapeutics. 2019; 9(1-s):113-120 
ISSN: 2250-1177                                                                                  [113]                                                                                 CODEN (USA): JDDTAO 
Available online on 15.02.2019 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted 
non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                     Research Article 
Dermal application of lactic acid based cream of a non pathogenic Kocuria 
marina (BMKO1) strain against Epidermophyton floccosum (MTCC 613) 
symptomatic excision mice model 
Soumya S Dash* and Smaranika Pattnaik 
Laboratory of Medical Microbiology, School of Life Sciences, Sambalpur University, Jyoti Vihar, Burla, 768019, Odisha, India 
 
ABSTRACT 
The aim of this study was to evaluate the antifungal efficacy of Kocuria marina (BMKo1) derived Lactic acid against Epidermophyton floccosum 
(MTCC-613) infections induced on male Swiss Albino mice model (Mus musculus).  For this purpose, the isolated strain was subjected to ‘flask 
fermentation’ and the Lactic acid produced as fermentation product, was quantified and analysed. Prior to preclinical test, healthy mice models 
of approximately 8 weeks old and 25-30 gm (weight) were subjected to intra-dermal administration for a period of 15 days to test for toxicity. 
Mortality, clinical signs, body weight changes were continually monitored. Then the mouse models were inoculated with 100 µl/ml (V/V) of E. 
floccosum (MTCC-613) spore suspensions following ‘Excision model’. After induction of the infection, the symptomatic mice groups were 
subjected to topical application of Kocuria lactic acid cream based formulation at a concentration of 1µl/ml (V/V). The naked eye observations 
were made on the infected lesions till the absolute deduction of infection of excised skin surfaces. The degrees of deduction of infection were 
converted into scores and the percentages (%) of deduction of infection were calculated and the average value was derived. There were 
inclusion of positive control (Fluconazole) and negative control (group with infection induced excision, but without any drug application) mice 
groups for the sake of comparison. Further, with absolute deduction of infection score observed in mice group, applied with Kocuria derived 
Lactic acid was akin to Fluconazole activity. However, the infection induced mice group was found to be with substantial increase of degree of 
infection. This study have curtain raised about the anti Epidermophyton infection activity of a cream based  Cell free Lactic acid derived from a 
non pathogenic strain of Kocuria marina on mouse models. 
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INTRODUCTION 
Anthrophillic dermatomycoses have a pivotal role to cause 
the dermal infections. Among them, Trichophyton rubrum, 
Trichophyton mentagrophytes and Epidermophyton floccosum 
are reported as invasive agents causing acute as well as 
chronic infections 1, 2, 3. As the invasiveness is an inherent 
characteristic of fungal strains, most of the prescribed drugs 
fail to inhibit the fungal growth inside the host tissue. 
Besides, many of marketed drugs are observed to be poorly 
delivered in the host body, thus making the fungal strain to 
evade the mechanism of action of drug. Strategies should be 
formulated to improve the bioavailability of the usual poorly 
absorbed drugs 4. More so, majority of the failures in new 
drug development have been attributed to poor water 
solubility of the drug 5.  
Hence, there is a need to develop antifungal agents from 
natural which can have the sufficient druggability 6. In drug 
development processes, both synthetic as well as natural 
products 7 are in practice because natural products are the 
single most important resource for drug leads 
(www.imm.ac.cn).  
In the context of development of drugs from natural sources, 
in vitro as well as in vivo studies are essential to launch a 
prodrug 8 in pharmaceutical industry. The in vivo studies 
specifically on animal models are important strategies to 
evaluate the drug delivery system as animal models are 
essential tools for biological research9.  
This present pursuit aims at evaluating Lactic acid extracted 
from an Actinomycetal strain namely Kocuria marina (Gene 
bank Accession No. MH752204) against the dermatomycotic 
infected (Epidermophyton floccosum, MTCC-613) 
symptomatic mice models. This is important to mention that 
Lactic acids, being weak organic acids 10 have immense 
importance in antifungal efficacy studies.   
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MATERIALS AND METHODS 
Lactic acid Extraction 
A strain of Actinobacteria namely Kocuria marina (BMKo1) 
was isolated and identified from a local nosocomial 
environment. The details of isolation and identification 
procedure are not included in this communication. The pure 
cultures of K. marina was subjected to fermentation study 
with different carbohydrates, namely, Glucose, Lactose, 
Sucrose, Dextrose and Mannitol. For this purpose, O/N 
(105cells/ml)) K. marina culture was inoculated to a series of 
fermentative carbohydrates broth and slants containing 1% 
carbohydrates and Phenol red. The tubes were incubated at 
370 C for a period of 24 hrs. Observation regarding 
fermentation (if any) was based on change in coloration of 
the medium both in broth and slant indicated by indicator 
Phenol red. Phenol red gives yellow coloration in acidic 
condition and remains red in neutral pH. 
After initial screening with different carbohydrate broths, 
Glucose broth was selected for lactic acid production by 
fermentation. Therefore, Nutrient Broth was prepared with 
1% glucose and phenol red was added as the indicator. Then 
O/N (105cells/ml)) nosocomial isolate was inoculated to the 
fermentative sugar broth. The inoculated Glucose broths 
were allowed to incubate at 370C for 48hrs. After complete 
fermentation (complete color change from Red to Yellow), 
the broth was subjected to centrifugation (3000 rpm for 15 
min in R4 Remi Centrifuge). The pellet was discarded and the 
supernatant was collected which was considered as the 
crude drug containing Lactic acid. The lactic acid produced 
by the nosocomial strain was catalogued as NLA (Nosocomial 
Lactic acid). 
Quantification of lactic acid 
The amount of Lactic acid produced by the Nosocomial strain 
into the medium was quantified by Titration method 11 of the 
cell free extract against 0.1M NaOH with Phenolphthalein as 
indicator. Therefore, 2 ml of NLA was mixed with distilled 
water in a conical flask to make the volume up to 10 ml. At 
the same time 2 drops of Phenolphthalein indicator was 
added to it. After that NaOH was taken in the burette and 
titration was carried out. The initial and end point reading 
were noted and finally the quantity of acid was calculated. 
Preparation of pharmaceutical formulation 
The test lactic acid was prepared in a cream based 
pharmaceutical formulation 12 for animal study. For this 
purpose, Bees wax and wool fat were melted together. Then 
liquid paraffin was added as the base material to it with 
gentle heating. Aqueous based purified lactic acid in 1:1 
concentration, warmed at same temperature as that of the 
base mixture was added to it and mixed thoroughly. The 
mixture was then stirred continuously till the mixture is 
cooled down. The stable mixture was stored (at room 
temperature) in a sterile vial for future.   
Toxicity test for the Lactic acid (LA) based cream  
The toxicity test for Lactic acid based cream was performed 
in the Dept. Of Pharmacology, VIMSAR, Burla, India with 
prior supervision of Pharmocologist of the said Institute. The 
crude sterile lactic acid was extracted from the strain of 
Kocuria marina (BMKo1). After quantitative estimation the 
lactic acid was made into a pharmaceutical cream 
formulation. The prepared cream was evaluated for various 
properties such as compatibility, drug content, viscosity, in 
vitro skin permeation etc.13. Three numbers of mice were 
taken as test mice members for the toxicity. The pelvic areas 
(1cm3) of rats were shaved using sterile razors. The Lactic 
acid based formulation was applied topically on the shaved 
skin surfaces of test rat group for a period of 15 days. The 
control group was kept unapplied. Mortality, clinical 
symptoms, body weight changes were continually monitored 
regularly by following standard in vivo study parameters. 
In vivo effect of Lactic acid based cream on symptomatic 
Excision Mice model  
The in vivo antidermatophytic activity was carried out in the 
Despande Lab. Pvt. Ltd, Bhopal, India. The test male Swiss 
albino rats were categorized into 4 groups, where one group 
(Group I) was asymptomatic and other 3 groups were 
symptomatic. The details in groupings of test mice are given 
in below figure 1. 
 
 
Figure 1: Grouping of Mice models 
Group I included the non symptomatic healthy mice 
members, Group II included mice members left untreated, 
Group III considered the symptomatic mice members treated 
with Fluconazole, and Group IV included the symptomatic 
mice members applied with LA based formulation. 
Group I mice members were not given any 
immunosupression as well as kept untreated, whereas group 
II, III, and IV were injected subcutaneously with the 
immunosupressant (500 mg, w/v of Estradiol Valerate) and 
were observed for a time period of 3 days. Then the flanks of 
mice were shaved with electric razor and the exposed area 
lightly abraded with a sterile scalpel. The Epidermophyton 
floccosum (MTCC-613) had been availed from IMTECH, 
Chandigarh. Conidia were obtained from 7 days old culture 
of test fungus by washing the surface of the media with 
sterile distilled water and a suspension (approx. 10 spores / 
µl) was prepared. All the four groups of mice were kept in 
separate cages for regular observation. Further, the lesions 
were visually examined daily to determine the severity and 
recovery of lesions and after a period of 7 days, the intensity 
of infection was measured in scores. On seventh day of 
infection the lesions were scored as follows: 0 (absence of 
lesion), 1 (appearance of erythema at infected site or new 
hair growth on the bald exposed area), 2 (moderate 
erythema spreading over entire infected site), 3 (intense 
erythema with abrasions, swelling and scaling), 4 (severely 
erythematous lesion with crusting spreading over the entire 
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exposed area). The average lesion scores were calculated for 
each group by dividing the sum of the lesion scored by the 
number of animals in the group. Moreover, the infected site 
of each animal was carefully examined daily throughout the 
treatment period to determine % recovery of infected site 
and treatment scores were given to mice groups as follows: 0 
(not cured), 1 (25% cured), 2 (50% cured), 3 (75% cured), 4 
(100% cured). The average scores were calculated. 
RESULTS & DISCUSSION 
The observations regarding different carbohydrate 
utilization by the test isolates have been given below. 
 
Table 1: Carbohydrate utilization by nosocomial isolates 
Carbohydrate Type Glucose Sucrose Dextrose Lactose Mannitol 
Inference + + + + + 
(NB: + ve indicating of Fermentative) 
From the results displayed in Table 1, it is observed that, the test strain was able to utilize the entire test Carbohydrates like 
Glucose, Sucrose, Dextrose, Lactose and even Mannitol. 
 
Figure 2: Depicting Carbohydrate fermentation of  K.marina 
It was observed that both the broth and slants meant for 
fermentation test were changed into yellow due to acid 
production (Figure 2). 
Quantification of lactic acid 
The titration experiment carried out to determine the 
quantity of Lactic acid produced by the bacterial cells 
indicated that the total volume of Sodium hydroxide (NaOH) 
consumed was 0.32 ml. Therefore, 0.32 / 1000×0.1 moles / l 
or 0.00003 moles / litre NaOH was required to titrate 10 5 
CFU/ml of the bacterial cell free extract containing the 
fermented product, i.e., Lactic acid. 
The quantification of produced Lactic acid / Number of 
bacterial cell has been done as follows, based on the 
Bronsted-Lowry theory: 
As the number of moles of NaOH= Number of moles of acid; 1 
mole of LA reacts with 1 mole of NaOH. 
So, 0.00003 mole of NaOH reacted with 0.00003 moles of LA.  
As the amount of crude cell free extract taken for titration 
was 2 ml, 
2ml of cell free Lactic acid = 0.002 litre of Cell free Lactic 
acid, i.e. 0.00003 moles of NaoH / 0.002 litre Cell free Lactic 
acid = 0.015 moles / litre Cell free Lactic acid. Therefore, the 
0.015 moles / liter cell free lactic acid was produced from 10 
2 CFU/ liter of bacterial cells in the medium containing only 
1% Glucose following 18 hrs of incubation. The results of the 
titration have been exhibited in Fig 3. 
 
                      
A                                              B                                               C 
Figure 3: Titration of cell free Lactic acid produced by K. marina; a: Flask containing cell free LA (yellow color), b: After 
titrated with NaoH color was Red, and c: Excess of NaOH (PH ≥7 color was deep pink) 
Dash et al                                                                                                                Journal of Drug Delivery & Therapeutics. 2019; 9(1-s):113-120 
ISSN: 2250-1177                                                                                  [116]                                                                                 CODEN (USA): JDDTAO 
Toxicity test for the LA based formulation 
After 15 days of observation on LA based formulation 
applied on the surfaces of mice models, it was found that the 
mice had developed immediate hypersensitivity (HS) 
reaction (Fig.4.a) which was observed as Rubor (Redness). 
However, the inflammation started to disappear after 72 hrs 
(Graph 1). There was no trace of HS after 15 days of regular 
application of lactic acid based formulated cream. Also there 
were no unscheduled diseases or deaths in any model during 
the study period.  The rats belonging to both groups were 
healthy and active. Initial development of HS is quite 
acceptable because, the HS is demonstration of a type of 
vertebrate defence mechanism. Mention may be made here 
that this toxicity testing of Kocuria derived LA on animal 
models helped to calculate the no observed adverse effect 
level (NOAEL) dose as this test is a prerequisite in clinical 
trials.
   
 
Figure 4.a: Skin surface of the representative mice 
model of Test group on day 1 showing immediate 
Hypersensitivity reaction 
 
 
Figure 4.b: Skin surface of the representative mice 
model of Control group on day 1 
 
 
Figure 4.c: Skin surface of the representative Mice of 
Test group on day 15 showing disappearance 
immediate Hypersensitivity reaction (HS) 
 
 
Figure 4.d: Skin surface of the representative Mice of 
Control group on day 15
 
Graph 1:  Depletion of immediate HS in test Mice model 
 
The appearance of redness on skin surface of test mice 
model on application of LA based formulation on 1st day 
could be due to local inflammation but not leading any 
cellulites on subsequent days give a clear proposition about 
the non toxicity of the said Lactic acid cream formulation. 
The fermentative product of a nosocomial Actinobacteria 
BMKo-1 was observed to be nontoxic on mice models when 
applied topically. 
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In vivo effect of Epidermophyton floccosum (MTCC 613) infection induced on mice model 
      
Figure 5: Representative mice skin surfaces induced with Epidermophyton infection a: Infected but restricted from any 
dermal application, b: applied with LA based formulation and c: Applied with the standard drug Fluconazole 
 
Table 2: Lesion Scores of the 4 animal groups 
LESION SCORES 
 Non symptomatic 
Healthy (I) 
Symptomatic and 
Untreated (II) 
  Treated with 
Fluconazole (III) 
Treated with LA 
formulation (IV) 
DAYS 1 2 3 Avg. 1 2 3 Avg. 1 2 3 Avg. 1 2 3 Avg 
1 0 0 0 0.0 1 1 1 1.0 1 1 1 1.0 1 1 1 1.0 
2 0 0 0 0.0 1 1 1 1.0 1 1 1 1.0 1 1 1 1.0 
3 0 0 0 0.0 1 1 1 1.0 1 1 1 1.0 1 1 1 1.0 
4 0 0 0 0.0 1 1 1 1.0 1 1 1 1.0 1 2 1 1.3 
5 0 0 0 0.0 2 1 2 1.7 1 1 1 1.0 1 2 1 1.3 
6 0 0 0 0.0 2 1 2 1.7 1 1 1 1.0 1 2 1 1.3 
7 0 0 0 0.0 3 2 2 2.3 1 1 1 1.0 1 2 1 1.3 
8 0 0 0 0.0 3 3 2 2.7 1 1 1 1.0 1 2 1 1.3 
9 0 0 0 0.0 4 3 3 3.3 1 1 1 1.0 2 2 1 1.7 
10 0 0 0 0.0 4 3 4 3.7 1 1 1 1.0 2 2 2 2.0 
11 0 0 0 0.0 4 4 4 4 1 1 1 1.0 2 2 3 2.3 
12 0 0 0 0.0 4 4 4 4 1 1 1 1.0 2 2 3 2.3 
13 0 0 0 0.0 4 4 4 4 1 1 1 1.0 2 2 3 2.3 
14 0 0 0 0.0 4 4 4 4 1 1 1 1.0 2 2 3 2.3 
15 0 0 0 0.0 4 4 4 4 1 1 1 1.0 2 2 3 2.3 
NB: Average lesion score: 0 (absence of lesion), 1 (appearance of erythema at infected site or new hair growth on the bald 
exposed area), 2 (moderate erythema spreading over entire infected site), 3 (intense erythema with abrasions, swelling and 
scaling), 4 (severely erythematous lesion with crusting spreading over the entire exposed area). 
a b c 
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Graph 2:  Regression analysis of lesion scores with no. of days 
 
Table 3: Reduction of Infection scores of mice group after treatment 
TREATMENT SCORES 
 Non symptomatic, 
Healthy  (I) 
Symptomatic and 
Untreated  (II) 
Treated with 
Fluconazole (III) 
Treated with LA 
formulation  (IV) 
DAYS 1 2 3 Avg. 1 2 3 Avg. 1 2 3 Avg. 1 2 3 Avg. 
1 0 0 0 0.0 0 0 0 0.0 1 1 1 1.0 1 1 1 1.0 
2 0 0 0 0.0 0 0 0 0.0 1 1 1 1.0 1 1 1 1.0 
3 0 0 0 0.0 0 0 0 0.0 1 1 1 1.0 1 1 2 1.3 
4 0 0 0 0.0 0 0 0 0.0 1 2 2 1.7 1 1 2 1.3 
5 0 0 0 0.0 0 0 0 0.0 2 2 2 2.0 1 2 2 1.7 
6 0 0 0 0.0 0 0 0 0.0 2 2 2 2.0 2 2 2 2.0 
7 0 0 0 0.0 0 0 0 0.0 3 3 3 3.0 2 2 2 2.0 
8 0 0 0 0.0 0 0 0 0.0 3 3 3 3.0 2 2 2 2.0 
9 0 0 0 0.0 0 0 0 0.0 3 3 3 3.0 2 2 2 2.3 
10 0 0 0 0.0 0 0 0 0.0 4 3 3 3.3 2 2 2 2.3 
11 0 0 0 0.0 0 0 0 0.0 4 3 3 3.3 2 2 2 2.3 
12 0 0 0 0.0 0 0 0 0.0 4 3 3 3.3 3 3 3 3.0 
13 0 0 0 0.0 0 0 0 0.0 4 3 4 3.7 3 3 3 3.0 
14 0 0 0 0.0 0 0 0 0.0 4 1 4 4.0 3 3 3 3.0 
15 0 0 0 0.0 0 0 0 0.0 4 1 4 4.0 3 3 3 3.0 
N.B. Treatment scores. 0 (not cured), 1 (25% cured), 2(50% cured), 3 (75% cured), 4(100% cured) 
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Graph 3:  Regression analysis of scores of reduction of infection with no. of days 
 
In the tests comprising in vivo application of Lactic acid 
based formulation on the test mice groups the observed 
results are reported in Table 2 & 3; Whereas the visual 
observation of test mice models are given in Figure 5. From 
the table it is observed that Group II symptomatic mice 
members remain uncured (with 0 scores). While Group IV 
symptomatic mice treated with LA based formulation were 
observed with 75% cure (Score 3) in the day 12th. Although 
there was 75% cure was observed with group III mice 
members applied with Fluconazole at day 7. In addition, the 
statistical regression analysis substantiated the fact that 
there was a positive correlation between the reduction 
intensity of infection with advancement of number of days. 
The results observed here have inferred about the in vivo 
antidermatomycotic activity of lactic acid based formulation 
on test mice models. The effectiveness was at par with the 
antimycotic activity of Fluconazole. This is further to 
mention that lactic acid which is a natural producing 
metabolite from an actinomycetal strain could able to cure 
the induced dermatophytic infection efficiently without 
imposing any toxic effect on the test mice models. All the 
four groups of the mice members were found to be healthy 
during the whole test period. 
CONCLUSION 
From this it is suggested that the Lactic acid (015 moles / L 
while titrating against NaOH, from 10 2 CFU/ L) based 
formulation had anti infective property with least toxicity, 
when tested against symptomatic mice members. The anti 
infective property was quite comparable with activity of 
standard drug. As it is relevant to mention that the results 
given here is unbiased as the whole set of experiments were 
carried out in Despande Lab Pvt. Ltd. following the ‘blind 
test’ rule. Hence this formulation has can be implemented as 
an excipient or drug active moiety in the antidermatomycotic 
drug designing processes. In other words, this study have 
curtain raised about the anti Epidermophyton infection 
activity of a cream based Lactic acid derived from a non 
pathogenic strain of Kocuria marina.  The result of this 
analysis has revealed an appreciable amount of druggability 
of a Lactic acid produced from an orphan nosocomial strain 
in the name of bio prospective activity by using the existing 
biological resources. 
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